Literature DB >> 16499568

Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H.

E S Reis1, D A Falcão, L Isaac.   

Abstract

The complement system participates in both innate and acquired immune responses. Deficiencies in any of the protein components of this system are generally uncommon and require specialized services for diagnosis. Consequently, complement deficiencies are clinically underscored and may be more common than is normally estimated. As C3 is the major complement component and participates in all three pathways of activation, it is fundamental to understand all the clinical consequences observed in patients for which this protein is below normal concentration or absent in the serum. C3 deficiencies are generally associated with higher susceptibility to severe infections and in some cases with autoimmune diseases such as systemic lupus erythematosus. Here, we review the main clinical aspects and the molecular basis of primary C3 deficiency as well as the mutations in the regulatory proteins factor I and factor H that result in secondary C3 deficiencies. We also discuss the use of animal models to study these deficiencies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16499568     DOI: 10.1111/j.1365-3083.2006.01729.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  68 in total

Review 1.  Complement genetics, deficiencies, and disease associations.

Authors:  Karine R Mayilyan
Journal:  Protein Cell       Date:  2012-07-10       Impact factor: 14.870

2.  Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity.

Authors:  Jerome P Jayasekera; E Ashley Moseman; Michael C Carroll
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

Review 3.  Common Genetic Variants in the Complement System and their Potential Link with Disease Susceptibility and Outcome of Invasive Bacterial Infection.

Authors:  Bryan van den Broek; Michiel van der Flier; Ronald de Groot; Marien I de Jonge; Jeroen D Langereis
Journal:  J Innate Immun       Date:  2019-07-03       Impact factor: 7.349

4.  Induction of complement C3a receptor responses by kallikrein-related peptidase 14.

Authors:  Katerina Oikonomopoulou; Robert A DeAngelis; Hui Chen; Eleftherios P Diamandis; Morley D Hollenberg; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-09-06       Impact factor: 5.422

Review 5.  From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; George Hajishengallis; Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2016-06-16       Impact factor: 3.144

6.  Safety profile after prolonged C3 inhibition.

Authors:  Edimara S Reis; Nadja Berger; Xin Wang; Sophia Koutsogiannaki; Robert K Doot; Justin T Gumas; Periklis G Foukas; Ranillo R G Resuello; Joel V Tuplano; David Kukis; Alice F Tarantal; Anthony J Young; Tetsuhiro Kajikawa; Athena M Soulika; Dimitrios C Mastellos; Despina Yancopoulou; Ali-Reza Biglarnia; Markus Huber-Lang; George Hajishengallis; Bo Nilsson; John D Lambris
Journal:  Clin Immunol       Date:  2018-10-10       Impact factor: 3.969

7.  A C3(H20) recycling pathway is a component of the intracellular complement system.

Authors:  Michelle Elvington; M Kathryn Liszewski; Paula Bertram; Hrishikesh S Kulkarni; John P Atkinson
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

Review 8.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

9.  Hereditary Homozygous C3 Deficiency.

Authors:  Jigna N Bathia; Priyankar Pal; Mandira Roy; Souvik Guha
Journal:  Indian J Pediatr       Date:  2017-04-24       Impact factor: 1.967

Review 10.  Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Authors:  Dimitrios C Mastellos; Edimara S Reis; Despina Yancopoulou; Antonio M Risitano; John D Lambris
Journal:  Semin Hematol       Date:  2018-02-14       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.